|
|
Article: Questcor Announces Collaboration With Fabre Kramer Pharmaceuticals for Worldwide Development of Hypnostat and Panistat.
- Article from:
- Business Wire
- Article date:
- June 27, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business/Health Editors
UNION CITY, Calif.--(BW HealthWire)--June 27, 2001
Questcor Pharmaceuticals, Inc. (AMEX:QSC) has signed a Letter of Understanding with Fabre Kramer Pharmaceuticals, Inc., of Houston, TX., to jointly pursue the worldwide development and commercialization of Hypnostat(TM) (intranasal triazolam) for insomnia and Panistat(TM) (intranasal alprazolam) for panic disorders. The Letter of Understanding anticipates the formation of a joint venture, with funding of the joint venture by Fabre Kramer.
Early Questcor clinical studies with Hypnostat(TM) have shown, at reduced doses, a faster onset of sleep and a longer period of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Fabre-Kramer Announces Positive Phase III Results ...
PR Newswire;
June 29, 2005 ;
692 words
... ... PRNewswire/ -- Fabre-Kramer Pharmaceuticals, Inc. announced today ... About Fabre-Kramer Fabre-Kramer Pharmaceuticals, headquartered in ... Koehler, Jr. of Fabre-Kramer Pharmaceuticals, Inc., +1-713 ...
|
|